STOCK TITAN
  1. Home
  2. News
  3. OKYO

OKYO Pharma Limited Ordinary Shares - OKYO STOCK NEWS

Welcome to our dedicated page for OKYO Pharma Ordinary Shares news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma Ordinary Shares stock.

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for inflammatory eye diseases and chronic pain conditions. The company is at the forefront of creating innovative treatments for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), both of which represent significant unmet medical needs in the ophthalmology sector.

One of OKYO Pharma's hallmark achievements is its development of the OK-101 ophthalmic solution. This drug candidate has shown promising results in pre-clinical studies, demonstrating dual-action anti-inflammatory and neuropathic corneal pain-reducing activities. The ongoing Phase 2 clinical trials are aimed at establishing the safety and efficacy of OK-101 in treating DED and NCP. Notably, these trials have successfully completed patient enrollment, with top-line results expected soon.

OKYO Pharma's approach leverages a unique membrane-anchored-peptide technology to ensure the prolonged presence of the drug in the ocular environment, thereby enhancing its therapeutic impact. In recent studies, OK-101 has exhibited statistically significant improvements in multiple dry eye-related symptoms, including stinging, burning, and blurred vision, as well as a notable reduction in conjunctival staining. These promising outcomes pave the way for future Phase 3 registration trials.

Financially, OKYO Pharma is well-positioned, with its ordinary shares listed on the NASDAQ Capital Market. The company continues to forge strategic partnerships and collaborations to bolster its research and development efforts. With a robust pipeline and a commitment to addressing the complex biology of eye diseases, OKYO Pharma stands as a pioneering entity in the biopharmaceutical landscape.

The latest developments include positive safety and efficacy results from the Phase 2 trials of OK-101, and the recent FDA clearance for OK-101's Investigational New Drug (IND) application for treating NCP. These milestones underscore the potential of OKYO Pharma's innovative solutions to significantly improve patient outcomes.

News

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Rhea-AI Summary
OKYO Pharma (NASDAQ: OKYO) announced statistically significant and durable improvements in ocular pain relief, conjunctival staining, tear film break-up time, burning/stinging, and blurred vision in a Phase 2 trial of OK-101 ophthalmic solution for inflammatory dry eye disease. The trial demonstrated exceptional safety and tolerability with no serious adverse events. Key findings support the proposed mechanism-of-action, paving the way for Phase 3 development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags
clinical trial
-
News

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Rhea-AI Summary
OKYO Pharma (NASDAQ: OKYO) to release Phase 2 OK-101 efficacy data on March 22nd, 2024, followed by a KOL Event on April 9th, 2024. The company is developing ocular therapies for inflammatory dry eye disease and neuropathic corneal pain, with promising preliminary results showing significant improvements in FDA-recognized endpoints.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences clinical trial
-
News

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Rhea-AI Summary
OKYO Pharma (NASDAQ: OKYO) announces the release of new efficacy data from the Phase 2 trial of OK-101 in dry eye disease, showing significant improvements in FDA-recognized endpoints. The company plans to advance OK-101 into Phase 3 trials in 2024 and evaluate its potential for treating neuropathic corneal pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
clinical trial
News

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Rhea-AI Summary
OKYO Pharma Receives FDA Clearance for OK-101 to Treat Neuropathic Corneal Pain, Launches Phase 2 Clinical Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.58%
Tags
fda approval
-
News

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

Rhea-AI Summary
OKYO Pharma Limited (NASDAQ: OKYO) announces the addition of distinguished ophthalmologists to its Scientific Advisory Board following positive safety and efficacy results in its Phase 2 trial of OK-101 for the treatment of dry eye disease and neuropathic corneal pain. The company plans to host a conference call in Q1, 2024 to provide further data on the trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
management
-
News

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

Rhea-AI Summary
OKYO Pharma Limited (OKYO) reports positive safety and efficacy results in its Phase 2 trial for OK-101 ophthalmic solution in subjects with Dry Eye Disease (DED). The trial established a clear path for further development in Phase 3 registration trials. OK-101 demonstrated statistically significant improvements in both signs and symptoms of DED, with a favorable safety profile. The company plans to advance OK-101 into Phase 3 clinical trials, targeting a highly differentiated dry eye product to help underserved patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
News

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Rhea-AI Summary
OKYO Pharma Limited (NASDAQ: OKYO) is presenting at Biotech Showcase in San Francisco to discuss the clinical development status of OK-101, a potential treatment for dry eye disease and neuropathic corneal pain. The company recently completed a phase 2 trial for OK-101, targeting a multi-billion-dollar market for dry eye disease. OKYO Pharma will also be participating in one-on-one partnering meetings at the conference, providing a networking platform for executives and investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
conferences
-
News

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Rhea-AI Summary
OKYO Pharma Limited (OKYO) announces the completion of the 240-patient phase 2 clinical trial of OK-101 for the treatment of inflammatory dry eye disease (DED) and neuropathic corneal pain. The company is on track to release top-line efficacy and safety data in December 2023. OK-101 has shown promising results in pre-clinical animal studies, and the successful execution of this trial is a crucial step in exploring its potential to treat millions of DED patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
clinical trial
-
News

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

Rhea-AI Summary
OKYO Pharma Limited has announced a registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per share, resulting in gross cash proceeds of $1.64M. Additionally, the company will extinguish $4.20M of payables by issuing 2,766,667 ordinary shares at the same offering price. This reduction in payables is seen as a significant endorsement of the company's strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
News

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Rhea-AI Summary
OKYO Pharma plans to initiate a clinical trial for OK-101 to treat Neuropathic Corneal Pain (NCP). The trial will be led by Dr. Pedram Hamrah and enrollment is planned for Q1 2024. OK-101 is also currently in a Phase 2 clinical trial for dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
none

FAQ

What is the current stock price of OKYO Pharma Ordinary Shares (OKYO)?

The current stock price of OKYO Pharma Ordinary Shares (OKYO) is $1.06 as of December 20, 2024.

What is the market cap of OKYO Pharma Ordinary Shares (OKYO)?

The market cap of OKYO Pharma Ordinary Shares (OKYO) is approximately 35.2M.

What is OKYO Pharma Limited known for?

OKYO Pharma Limited is known for developing innovative therapies for inflammatory eye diseases and chronic pain conditions, particularly Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).

What are the key products of OKYO Pharma?

The key product of OKYO Pharma is the OK-101 ophthalmic solution, which is currently in Phase 2 clinical trials for treating Dry Eye Disease and Neuropathic Corneal Pain.

What recent achievements has OKYO Pharma accomplished?

Recently, OKYO Pharma reported positive safety and efficacy results from its Phase 2 trial of OK-101 for Dry Eye Disease and received FDA clearance for an Investigational New Drug application for the treatment of Neuropathic Corneal Pain.

What is the significance of OK-101 in the treatment of Dry Eye Disease?

OK-101 has shown promising results in reducing inflammation and neuropathic pain in Dry Eye Disease patients, demonstrating statistically significant improvements in multiple symptoms and signs.

How is OKYO Pharma's financial condition?

OKYO Pharma is financially stable, with its ordinary shares listed on the NASDAQ Capital Market, providing a strong foundation for ongoing research and development activities.

What are the future plans for OK-101?

OKYO Pharma plans to advance OK-101 into Phase 3 clinical trials for Dry Eye Disease and initiate a Phase 2 trial for treating Neuropathic Corneal Pain in 2024.

What is Dry Eye Disease (DED)?

Dry Eye Disease is a condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to inflammation and discomfort. It affects millions of people globally.

What is Neuropathic Corneal Pain (NCP)?

Neuropathic Corneal Pain is a chronic eye condition caused by nerve damage and inflammation in the cornea, leading to severe pain and sensitivity. Currently, there are no FDA-approved treatments for NCP.

How does OK-101 work?

OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, found on immune cells in the eye. It reduces inflammation and pain by enhancing its residence time in the ocular environment.

Where can I find more information about OKYO Pharma?

For more information about OKYO Pharma, please visit their official website at www.okyopharma.com.

Stock OKYO logo
OKYO Pharma Limited Ordinary Shares

Nasdaq:OKYO

OKYO Rankings

#5061 Ranked by Market Cap
N/A Ranked by Dividends

OKYO Stock Data

35.19M
24.49M
27.61%
2.96%
0.69%
Biotechnology
Healthcare
Link
United States of America
London